Prostate Testing for Cancer and Treatment (ProtecT) Feasibility Study
Completed
- Conditions
- Prostate cancerCancerMalignant neoplasm of prostate
- Registration Number
- ISRCTN08435261
- Lead Sponsor
- Department of Health (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 150
Inclusion Criteria
Men aged 50-69 years from specific primary care centres in the three cities were invited to attend a 30-minute prostate check clinic appointment in which they were informed about the study and asked to consent to a prostate specific antigen (PSA) test. Men with a raised PSA (initially =3.0 ng/ml if 50?59 years; =4.0 ng/ml if 60?69 years; but changed to =3.0 ng/ml for all men after 1 year) were invited for biopsy. Men with confirmed localised prostate cancer were invited to participate in a randomised trial of recruitment strategies.
Exclusion Criteria
Men considered by the GP to be unfit for any of the potential treatments (ie those terminally ill or with serious co-morbidity).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome was the proportion of patients accepting randomisation to the treatment trial. Number of eligible patients randomised by nurses and urologists
- Secondary Outcome Measures
Name Time Method Cost effectiveness of nurses and urologists